(11) 98705-3426
TrademarkIQ iconTrademarkIQ
Back to search
Official data from USPTO

ICONIS BIOCEUTICALS

Did you know this trademark is already registered in United States?

Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.

Active USPTO registrationType: CombinedOffice: United States

Quick snapshot

ICONIS BIOCEUTICALS

ST13

US500000086766081

Class

5

Filing

86766081

Registration

5067123

Risk and opportunity diagnosis

Executive reading for naming, filing, and monitoring decisions.

USPTO status

Active USPTO registration

Case type

Application and registration

Recorded events

34

Latest update

04/18/2026

Trademark type

Combined

Nice classes

5

Filing date

09/23/2015

Registration date

10/25/2016

Expiration date

-

Complete case details

Structured fields from the responsible authority and the official record.

Status date

04/04/2023

Last transaction

04/18/2026

Responsible office

United States Patent and Trademark Office

Status code

701

Official register

Principal Register

First use anywhere

10/17/2014

First use in commerce

07/24/2015

Drawing code

3

Owner type

03

Owner location

South Jordan, UT, US

Examiner

PARADEWELAI, BENJI YUEN

Current location

Historical data usage

Mark description

The mark consists of a chemical compound molecular structure with 6 circles in a circle formation, 6 circle in a larger circle formation with 1 circle between a circle. The name "ICONIS" in 3D Font then the name "Bioceuticals" under the name "Iconis".

Holders and representatives

Holders

Iconis Bioceuticals, Inc.

Representatives

Iconis Bioceuticals, Inc.

Technical classification

Nice Classes

Class 5

Vienna Codes

No Vienna codes available.

Goods and services

Class 5

Herbs for medicinal purposes; Natural herbal supplements; Nutritional supplements; Vitamins

Publications

History of USPTO decisions and trademark events.

34 publications found

PR89

POST REGISTRATION ACTION MAILED - SEC. 8 & 9

04/17/2026

APRE

CASE ASSIGNED TO POST REGISTRATION PARALEGAL

04/17/2026

E89R

TEAS SECTION 8 & 9 RECEIVED

02/09/2026

REM2

COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED

10/26/2025

NAS8

NOTICE OF ACCEPTANCE OF SEC. 8 - E-MAILED

04/04/2023

8.OK

REGISTERED - SEC. 8 (6-YR) ACCEPTED

04/04/2023

APRE

CASE ASSIGNED TO POST REGISTRATION PARALEGAL

04/01/2023

ES8R

TEAS SECTION 8 RECEIVED

08/17/2022

REM1

COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED

10/25/2021

R.PR

REGISTERED-PRINCIPAL REGISTER

10/25/2016

PUBO

PUBLISHED FOR OPPOSITION

08/09/2016

NPUB

NOTICE OF PUBLICATION

07/20/2016

CNSA

APPROVED FOR PUB - PRINCIPAL REGISTER

07/01/2016

TEME

TEAS/EMAIL CORRESPONDENCE ENTERED

06/08/2016

CRFA

CORRESPONDENCE RECEIVED IN LAW OFFICE

06/08/2016

ERFR

TEAS REQUEST FOR RECONSIDERATION RECEIVED

06/08/2016

TEME

TEAS/EMAIL CORRESPONDENCE ENTERED

06/04/2016

CRFA

CORRESPONDENCE RECEIVED IN LAW OFFICE

06/03/2016

ERFR

TEAS REQUEST FOR RECONSIDERATION RECEIVED

06/03/2016

GNFN

NOTIFICATION OF FINAL REFUSAL EMAILED

02/26/2016

GNFR

FINAL REFUSAL E-MAILED

02/26/2016

CNFR

FINAL REFUSAL WRITTEN

02/26/2016

ARAA

ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED

02/19/2016

REAP

TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED

02/19/2016

TEME

TEAS/EMAIL CORRESPONDENCE ENTERED

02/19/2016

CRFA

CORRESPONDENCE RECEIVED IN LAW OFFICE

02/19/2016

TROA

TEAS RESPONSE TO OFFICE ACTION RECEIVED

02/19/2016

GNRN

NOTIFICATION OF NON-FINAL ACTION E-MAILED

01/12/2016

GNRT

NON-FINAL ACTION E-MAILED

01/12/2016

CNRT

NON-FINAL ACTION WRITTEN

01/12/2016

DOCK

ASSIGNED TO EXAMINER

01/11/2016

MDSC

NOTICE OF DESIGN SEARCH CODE E-MAILED

09/30/2015

NWOS

NEW APPLICATION OFFICE SUPPLIED DATA ENTERED

09/29/2015

NWAP

NEW APPLICATION ENTERED

09/26/2015

Continuous trademark protection

Get notified about every new filing that threatens ICONIS BIOCEUTICALS or your mark.

Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.